NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has been granted a license from California allowing the Australian firm to sell its BrevaGen breast cancer test in that state.

The Laboratory Field Services Unit of the California Department of Public Health has granted a license to Genetic Technologies' Australian-based laboratory, the firm said. The state represents about 11 percent of the total number of breast cancer incidents in the US with more than 25,000 new cases of breast cancer diagnosed annually, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.